New Crown Vaccine Express! WHO adds AstraZeneta AZD1222 to its list of emergency uses: routine refrigeration, 2-pin immunization, no profitable global supply!

February 16, 2021 / / -- At present, the outbreak of new crown pneumonia abroad is still spreading rapidly.
according to Baidu's Real-Time Big Data Report on the Outbreak of New Coronavirus Pneumonia, as of 22:00 on February 16, 2021, more than 100 million cases (109.76 million) had been confirmed worldwide and more than 2.42 million deaths had been reported worldwide.
recently, AstraZeneca announced that its adenovirus vaccine COVID-19 Vaccine AstraZeneca (formerly known as AZD1222), developed with Oxford University, has been placed on the Emergency Use List (EUL) by the World Health Organization (WHO) for active immunization of people aged 18 and over, including those aged 65 and over, to prevent COVID-19.
it is worth mentioning that the COVID-19 Vaccine AstraZeneca vaccine can be stored, transported and treated for at least 6 months under conventional refrigeration conditions (2-8 degrees C/36-46 degrees Fahrenheit) and used in existing medical settings.
licensing of the COVID-19 Vaccine AstraZeneca vaccine produced by AstraZeneca and the COVISHIELD vaccine (coVID-19 Vaccine AstraZeneca vaccine in India) produced by the Indian Serum Research Institute (SII) will enable the global access to the vaccine during the COVID-19 pandemic.
EUL allows 2 doses of the vaccine every 4-12 weeks.
clinical trials have shown that the programme is safe and effective in preventing symptomatic COVID-19, with no serious cases or hospitalizations after 14 days of second injection.
WHO Expert Strategic Advisory Group on Immunization (SAGE) recommends an injection interval of 8-12 weeks.
addition, they recommend using the vaccine in countries where new variants, including the B1.351 variant in South Africa, are endemic.
assali has promised to make no profits by making its COVID-19 vaccine available to as many countries as possible during the pandemic.
June 2020, the company announced a sub-licensing agreement with SII to produce and supply up to 1 billion doses of vaccine to low- and middle-income countries.
AstraZeneta is the first global pharmaceutical company to join COVAX (WHO's New Coronary Pneumonia Vaccine Implementation Program) in June 2020.
the Global Mechanism is working to accelerate the development and production of new COVID-19 tools and to provide them with equitable access worldwide to all participating countries, regardless of income level.
now, AstraZenecom and SII will work with COVAX Facility to begin supplying vaccines around the world, most of which will be shipped to low- and middle-income countries as soon as possible.
to deliver more than 300 million doses of vaccine to 145 countries through COVAX in the first half of 2021.
doses will be distributed fairly in accordance with the COVAX distribution framework. Pascal Soriot, chief executive of
AstraZeneta, said: "Today's approval recognises that the vaccine can be used to help protect people around the world, including people over 65, as well as countries where SARS-CoV-2 is endemic to different virus variants.
this is a major step towards ensuring global access to our vaccines and helping us meet our public health commitments to achieve broad, equitable and unprofitable access to vaccines during pandemics.
s been waiting for this final milestone," said Adair Poonawalla, chief executive of the Indian Serum Research Institute (SII).
I am pleased and relieved that with WHO's EUL, we will be able to begin delivering vaccines to Africa and other low- and middle-income countries immediately.
countries with large populations must be protected as soon as possible.
COVID-19 Vaccine AstraZeneca (formerly known as AZD1222) was co-invented by Oxford University and its spin-off company, Vaccitech.
it uses a weakened version based on the common cold virus (adenovirus) to replicate the defective chimpanzee virus vector, which causes infections in chimpanzees and contains genetic material for the SARS-CoV-2 virus prickly protein.
the vaccine, it produces surface prickly proteins that stimulate the immune system to attack the SARS-CoV-2 virus.
WHO's approval was based on a summary analysis of the efficacy of 11,636 participants aged 18 and over from phase III trials in the United Kingdom and Brazil conducted at Oxford University, which resulted in 131 cases of symptomatic COVID-19 infection.
overall safety is based on an interim analysis of aggregated data from four clinical trials conducted in the UK, Brazil and South Africa, including 23,745 participants aged 18 or over.
ASIL's COVID-19 vaccine is well- resistant and no serious vaccine-related safety incidents have occurred.
participants come from different ethnic and geographic groups and are physically healthy or have stable underlying diseases.
as well as the Oxford-led scheme, AstraZeneta is conducting large-scale trials in the US and around the world.
Oxford University and AstraZeneta are expected to join up to 60,000 subjects worldwide.
AstraZeneta's COVID-19 vaccine has been licensed for conditional or emergency use in more than 50 countries, and WHO's EUL will now accelerate access to the vaccine in up to 145 countries through COVAX Facility.
() Original source: AstraZeneca COVID-19 vaccine authorised for emergency use by the World Health Organization